Dr. Ballinger Shares Her Top News From ASCO 2024
Tarah Ballinger, MD, discusses what she considers to be the biggest developments from the 2024 ASCO Annual Meeting.
Breast cancer was a major area of development at this year's American Society of Clinical Oncology (ASCO) Annual Meeting. In particular, clinical trials of antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (Enhertu; T-DXd) and sacituzumab govitecan (Trodelvy) offered significant insights into treatment options and sequencing for patients with breast cancer.
Tarah Ballinger, MD, is an associate professor of clinical medicine at Indiana University School of Medicine and the Vera Bradley Foundation Scholar in Breast Cancer Research, who specializes in breast medical oncology, shared her highlights from the 2024 ASCO Annual Meeting.
Transcription:
0:05 | I think in breast cancer this year, we're going to see a lot of updates from some of the different antibody-drug conjugates. I think these are great because there's going to be so many more options for our patients living with metastatic disease. The question and what I hope to hear in some of the discussions is how we're going to best sequence all of these different drugs so that we can ultimately improve outcomes for our patients.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
